SCHEMBL9923342

SCHEMBL9923342

N#Cc1cnn2cnnc2c1O

nearest known ligand 0.40

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 1/20 0.40
EPHB3 P54753 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9923344 0.79 CDK2 (0.40) CDK2
SCHEMBL16503594 0.79 CDK2 (0.46) CDK2
SCHEMBL9923287 0.72 CDK2 (0.60) CDK2EPHB3
SCHEMBL9923282 0.70 CDK2 (0.41) CDK2EPHB3
SCHEMBL9920402 0.69
SCHEMBL9923417 0.69 MEN1 (0.36) CDK2
SCHEMBL9923350 0.68 CDK2 (0.39) CDK2
SCHEMBL1160399 0.67 CDK2 (0.49) CDK2EPHB3
SCHEMBL21855498 0.64 CDK2 (0.54) CDK2
SCHEMBL12681980 0.63 CDK2 (0.35) CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149691-A1 Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149691-A1 Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors JAK1, JAK2, JAK3 CDK2 423/4885EPHB3 3982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.